Literature DB >> 9489864

Alpha1-adrenoceptors in testosterone-induced prostatic hypertrophy.

L Auger-Pourmarin1, P Roubert, P E Chabrier.   

Abstract

Modifications of rat prostatic alpha1-adrenoceptors were investigated in testosterone-induced prostatic hypertrophy. [3H]prazosin bound to a single class of binding sites with a dissociation constant of 57.9+/-5.02 pM. The greater part of the binding capacity (24.6+/-1.02 fmol/mg protein) was made up of chloroethylclonidine-resistant binding sites that showed high-affinity for oxymetazoline and 5-methyl-urapidil, and was identified as alpha1A-adrenoceptors. The remaining chloroethylclonidine-sensitive binding sites that showed low-affinity for oxymetazoline and 5-methyl-urapidil were preferentially identified as alpha1B-adrenoceptors. mRNA for the three alpha1-adrenoceptors (alpha1a, alpha1b and alpha1d) was detected. Testosterone administration produced a 23% decrease of alpha1-adrenoceptor density, likely by an increase of prostatic glandular epithelium and a decrease in the relative proportion of smooth muscle, thus of alpha1-adrenoceptor density. The steady state level of mRNAs for alpha1-adrenoceptors was not modified by testosterone treatment. These results indicate that prostate alpha1-adrenoceptors are not affected in the prostatic hypertrophy induced by testosterone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489864     DOI: 10.1016/s0014-2999(97)01432-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Effects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate.

Authors:  Y Homma; K Hamada; Y Nakayama; G Tsujimoto; K Kawabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.

Authors:  Xinhua Zhang; Ning Zang; Yu Wei; Jin Yin; Ruobing Teng; Allen Seftel; Michael E Disanto
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-25       Impact factor: 4.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.